GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celularity Inc (NAS:CELU) » Definitions » Price-to-Owner-Earnings

Celularity (Celularity) Price-to-Owner-Earnings : (As of May. 24, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Celularity Price-to-Owner-Earnings?

As of today (2024-05-24), Celularity's share price is $3.41. Celularity does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Celularity's Price-to-Owner-Earnings or its related term are showing as below:


CELU's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 32.4
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-24), Celularity's share price is $3.41. Celularity's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $-10.20. Therefore, Celularity's PE Ratio for today is At Loss.

As of today (2024-05-24), Celularity's share price is $3.41. Celularity's EPS without NRI for the trailing twelve months (TTM) ended in was $-7.44. Therefore, Celularity's PE Ratio without NRI for today is At Loss.

During the past 3 years, Celularity's highest PE Ratio without NRI was 35.33. The lowest was 0.00. And the median was 14.02.


Celularity Price-to-Owner-Earnings Historical Data

The historical data trend for Celularity's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celularity Price-to-Owner-Earnings Chart

Celularity Annual Data
Trend Dec20 Dec21 Dec22
Price-to-Owner-Earnings
- - -

Celularity Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Celularity's Price-to-Owner-Earnings

For the Biotechnology subindustry, Celularity's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Celularity's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Celularity's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Celularity's Price-to-Owner-Earnings falls into.



Celularity Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Celularity's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=3.41/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Celularity  (NAS:CELU) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Celularity Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Celularity's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Celularity (Celularity) Business Description

Traded in Other Exchanges
N/A
Address
170 Park Avenue, Florham Park, NJ, USA, 07932
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases.
Executives
Kok Thay Lim director 22ND FLOOR, WISMA GENTING, JALAN SULTAN ISMAIL, KUALA LUMPUR N8 50250
Robert J Hariri director, officer: Chief Executive Officer 341 MENDHAM ROAD, BERNARDSVILLE NJ 07924
Ling Geoffrey M.d. director C/O CATALYST BIOSCIENCES, INC., 611 GATEWAY BOULEVARD, SUITE 710, SOUTH SAN FRANCISCO CA 94080
Berhad Genting 10 percent owner 24TH FLOOR, WISMA GENTING, JALAN SULTAN ISMAIL, KUALA LUMPUR N8 50250
Adrian Kilcoyne officer: See Remarks 533 AIRPORT BLVD., SUITE 400, BURLINGAME CA 94010
John Sculley director C/O KALEIDO BIOSCIENCES, INC., 65 HAYDEN AVENUE, LEXINGTON MA 02421
Kyle Fletcher officer: General Counsel CELULARITY INC., 170 PARK AVE., FLORHAM PARK NJ 07932
Peter Diamandis director 4640 ADMIRALTY WAY, SUITE 500, MARINA DEL REY CA 90292
Dean C Kehler director C/O TRIMARAN CAPITAL PARTNERS, 622 THIRD AVENUE, 35TH FLOOR, NEW YORK NY 10017
Robin L Smith director C/O PHASE III MEDICAL, INC., 330 SOUTH SERVICE ROAD, SUITE 120, MELVILLE NY 11747
Marc Mazur director 31 WEST 52ND ST. 17TH FLOOR, NEW YORK NY 10019
Diane L. Parks director 29 EMMONS DRIVE, SUITE B-10, PRINCETON NJ 08540
Bradley Glover director, officer: Chief Technology Officer C/O CELULARITY INC., 170 PARK AVENUE, FLORHAM PARK NJ 07932
Stephen Brigido officer: Pres, Functional Regeneration C/O CELULARITY INC., 170 PARK AVENUE, FLORHAM PARK NJ 07932
Anne Jones director, officer: Chief Business Officer C/O CELULARITY INC., 170 PARK AVENUE, FLORHAM PARK NJ 07932

Celularity (Celularity) Headlines

From GuruFocus

Celularity Appoints Paul Graves as Chief Communications Officer

By Stock market mentor Stock market mentor 01-04-2023